Close

Business & Industry

Cross-Functional Executive Alignment Improving Biotech Business Execution

Establishing a synchronized leadership structure serves as the cornerstone of operational success within the modern pharmaceutical sector. As companies move away from traditional silos, the integration of scientific expertise with commercial acumen becomes a mandatory requirement for managing the...

Demand Sensing Analytics Improving Pharmaceutical Supply Chain Responsiveness

The pharmaceutical industry has traditionally relied on historical data and long-term forecasts to drive production and distribution decisions. However, this reactive approach often leads to significant inefficiencies, such as excessive inventory levels or critical stockouts. The introduction of demand...

Supply Chain Resilience Planning Improving Pharmaceutical Operational Continuity

Global pharmaceutical markets require a sophisticated approach to risk management that moves beyond simple contingency planning. Establishing a framework for resilience involves identifying potential failure points across the entire lifecycle of a drug product, from raw material procurement to...

BioNTech and Gilead Partner for Pumitamig Clinical Trial

BioNTech SE has officially entered into a clinical trial collaboration and supply agreement with Gilead Sciences Inc. to evaluate the bispecific immunomodulator pumitamig in combination with the TROP2-directed antibody-drug conjugate (ADC) sacituzumab govitecan. Announced on October 22, 2026, this...

Cencora to Acquire American Oncology Network in $2.4 Billion Deal

Cencora has signed a definitive agreement to acquire American Oncology Network, a physician-led network of more than 350 oncology providers operating across 21 states, in a transaction that values AON at approximately $2.4 billion. The deal is set to...

Merck Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA has entered into an agreement to acquire British biotech Silence Therapeutics for $1.3 billion in a fully cash-based transaction, securing the German pharmaceutical company's access to a compelling short interfering RNA (siRNA) drug development platform and a...

METiS TechBio and Eli Lilly Join Forces for Next-Generation Tissue-Specific LNP Delivery Technologies

METiS TechBio has announced a strategic collaboration with Eli Lilly and Company to research and develop next-generation lipid nanoparticle (LNP)-based delivery solutions, leveraging METiS's proprietary AI-driven platform to enable precise, tissue-specific delivery of therapeutic modalities. Under the terms of the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »